Ironwood Pharma (IRWD) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
August 4, 2016 4:10 PM EDTIronwood revenue increased 96% to $54.4 million in 2Q 2016 compared to 2Q 2015
LINZESS® (linaclotide) U.S. net sales increased 34% to $150.5 million in 2Q 2016 over 2Q 2015; net profit for the brand increased to $58 million from $15 million
On track to launch two priority franchise products: ZURAMPIC® (lesinurad) in October 2016 for hyperuricemia associated with uncontrolled gout and 72 mcg linaclotide in early 2017 for chronic idiopathic constipation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
